Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional

Notice Number: NOT-DA-19-047

Key Dates

Release Date: May 22, 2019
Estimated Publication Date of Funding Opportunity Announcement: August 01, 2019
First Estimated Application Due Date: November 01, 2019
Earliest Estimated Award Date: June 01, 2020
Earliest Estimated Start Date: July 01, 2020

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and institutions. The purpose of this notice is to allow potential applicants sufficient time to develop meaningful collaborations and projects.

The FOA is expected to be published in August 2019 with an expected application due date in November 2019.

Research Initiative Details

The CTN is comprised of research Nodes that serve as research and training centers, with numerous collaborating healthcare organizations or clinical research sites, and two coordinating centers. The CTN program is administered within NIDA through the Center for the Clinical Trials Network (CCTN). NIDA plans to continue supporting the CTN research infrastructure to build on the broad portfolio of research conducted in the CTN.

Applicants will be encouraged to provide descriptions of their ability to engage diverse patients in areas highly impacted by substance use; expertise with innovative research tools and constructs and capacity to conduct efficacy, effectiveness and implementation research; ability to leverage digital technologies and electronic platforms such as mobile health tools and electronic health record systems; clinical trial expertise evaluating medications and behavioral strategies to address current and emerging trends in substance misuse/SUD (e.g. stimulant misuse); and ability to conduct pragmatic addiction research embedded in general medical settings and specialty care settings with an emphasis on sustainability.

Applications proposing new Nodes and continued support of existing Nodes are encouraged. Applications proposing Multiple Principal Investigator (MPI) collaborations, including collaborations between institutions in different states, are encouraged. NIDA has an interest in extending the reach of the CTN to regions of the country that are not currently represented in the network.

Funding Information

Estimated Total Funding TBD
Expected Number of Awards TBD
Estimated Award Ceiling TBD
Primary CFDA Numbers 93.279

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Betty Tai, Ph.D.
National Institute on Drug Abuse (NIDA)
301-443-2397
btai@nida.nih.gov